Camu-camu decreases hepatic steatosis and liver injury markers in overweight, hypertriglyceridemic individuals: A randomized crossover trial

Anne-Laure Agrinier, Arianne Morissette, Laurence Daoust, Théo Gignac, Julie Marois, Thibault Varin, Geneviève Pilon, Éric Larose, Claudia Gagnon, Yves Desjardins,

Cell Reports Medicine · 2024 · 11 citations · 50 references

DOIFull text

Open access

Concepts

Abstract

Non-alcoholic fatty liver disease (NAFLD), recently referred to as “metabolic dysfunction-associated steatotic liver disease” (MASLD), affects 25% of the adult population with no effective drug treatments available. Previous animal studies reported that a polyphenol-rich extract from the Amazonian berry camu-camu (CC) prevented hepatic steatosis in a mouse model of diet-induced obesity. This study aims to determine the impact of CC on hepatic steatosis (primary outcome) and evaluate changes in metabolic and gut microbiota profiles (exploratory outcomes). A randomized, double-blind, placebo-controlled crossover trial is conducted on 30 adults with overweight and hypertriglyceridemia, who consume 1.5 g of CC capsules or placebo daily for 12 weeks. CC treatment decreases liver fat by 7.43%, while it increases by 8.42% during the placebo intervention, showing a significant difference of 15.85%. CC decreases plasma aspartate and alanine aminotransferases levels and promotes changes in gut microbiota composition. These findings support that polyphenol-rich prebiotic may reduce liver fat in adults with overweight, reducing the risk of developing NAFLD. • Camu-camu reduces hepatic steatosis in adults with overweight and hypertriglyceridemia • Camu-camu supplementation decreases plasma AST and ALT levels • Camu-camu supplementation alters gut microbiota composition Agrinier et al. demonstrate that camu-camu (CC) supplementation reduces liver fat and improves liver injury markers in individuals with overweight and hypertriglyceridemia. CC also alters gut microbiota composition, supporting its potential as a polyphenol-rich prebiotic supplement for reducing non-alcoholic fatty liver disease risk.

References

50